Clinical trial · Observational
CT Imaging for Guiding PA-TACE for HCC
CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma
NCT06156748CI-TRIAL-00092700completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| postoperative adjuvant transarterial chemoembolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Hepatectomy alone
- interventionNames
- Procedure: postoperative adjuvant transarterial chemoembolization
- label
- PA-TACE
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.
- description
- Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * CT scans acquired no more than one month before surgery * Confirmation of HCC diagnosis by pathological examination * Curative surgical resection Exclusion Criteria: * Prior antitumor treatment * Macrovascular thrombosis or metastasis * Perioperative mortality * Unqualified image artifacts * Tumor rupture * MVI status not reported
References
Publications (1)
- DERIVEDLi X, Liang X, Li Z, Liang J, Qi Z, Zhong L, Geng Z, Liang W, Quan X, Liang C, Liu Z. A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study. Int J Surg. 2024 May 1;110(5):2556-2567. doi: 10.1097/JS9.0000000000001191. PMID 38377071